Loading...
•
Mar 31, 2023
Acelyrin Q1 2023 Earnings Report
Reported financial results for the first quarter ended March 31, 2023 and highlighted recent corporate achievements.
Key Takeaways
ACELYRIN reported a net loss of $176.5 million for Q1 2023, including a one-time $123.1 million IPR&D charge and $10.0 million license payment related to the ValenzaBio acquisition. The company's cash and cash equivalents totaled $289.2 million at the end of the quarter, with expectations to fund operations through key milestones using IPO proceeds and existing cash.
Initial Public Offering generated gross proceeds of $621 million and net proceeds of $573.7 million.
Cash position strong with $289.2 million at the end of Q1 2023.
Top-line data for the Phase 2b/3 randomized controlled study of izokibep in Hidradenitis Suppurativa (HS) accelerated to Q3 2023.
Lonigutamab and SLRN-517 are actively enrolling in Phase 1/2 Proof-of-Concept Studies.
Forward Guidance
ACELYRIN expects the combined cash balance of $862.9 million as of March 31, 2023 to fund operations through key value-driving milestones across all three clinical programs and beyond.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...